# US 6,727,322 B2 · Amphiphilic networks, implantable immunoisolatory devices, and methods of preparation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,322 B2
- Document ID: US6727322B2
- Status: Granted
- Kind: B2
- Application number: 10/114,647
- Filed: 2002-04-01
- Published: 2003-12-18
- Granted: 2004-04-27
- Earliest claimed: 2002-04-01
- Assignees: The University of Akron
- Inventors: Joseph P. Kennedy; Irada S. Isayeva
- Web page: https://patentgrep.com/patent/US6727322B2

## CPC

- C08F 290/042: {Polymers of hydrocarbons as defined in group C08F10/00}
- C08F: MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS

## Abstract

The present invention provides high mechanical strength amphiphilic polymeric networks and implantable biological devices made therefrom that are capable of encasing and, thus, immunoisolating biological material from an immunological response of a host individual. The present invention also provides methods for making the amphiphilic networks and implantable biological devices. The present invention also provides a method for the treatment of type I diabetes mellitus comprising the steps of encasing a sufficient amount of islet of Langerhans cells within said biological device, wherein said biological device is capable of immunoisolating said encased islet cells upon implantation into an individual; implanting said biological device into a diabetic host individual; allowing said implanted biological device to remain implanted in said diabetic individual for a time sufficient to normalize the blood glucose level in said diabetic individual.

## Claims

### Claim 1

An amphiphilic network comprising the reaction product of hydrophobic crosslinking agents and hydrophilic monomers, wherein said hydrophobic crosslinking agents are multi-arm multi-telechelic polyisobutylene stars having acrylate or methacrylate end caps and represented by formula (I):
wherein R1 is polyisobutylene represented by formula (II):
wherein x is the degree of polymerization of said polyisobutylene;
wherein R2 is either H or CH3;
wherein A is a moiety that connects R1 to said acrylate or methacrylate end caps;
wherein n is an integer from 4 to 16; and
wherein said hydrophilic monomers are derived from an acrylate selected from the group consisting of formulas (III), (IV) and (V):
wherein R3 is hydrogen or methyl, R4 is an alkylene group having from about 2 to about 4 carbon atoms, and R5 and R6 may be the same or different and each is hydrogen or an alkyl radical having 1 to about 4 carbon atoms.

### Claim 2 (depends on 1)

The amphiphilic network of claim 1, wherein A comprises at least:

### Claim 3 (depends on 1)

The amphiphilic network of claim 1, wherein the Mn of said hydrophobic crosslinking agent is at least about 2,000 g/mol.

### Claim 4 (depends on 3)

The amphiphilic network of claim 3, wherein the Mn of said hydrophobic crosslinking agent is from about 2,000 g/mol to about 100,000 g/mol.

### Claim 5 (depends on 1)

The amphiphilic network of claim 1, wherein the ratio of said hydrophobic crosslinking agent to said hydrophilic monomer is from about 80:20 to about 20:80 by weight.

### Claim 6

A method of forming an amphiphilic network comprising the steps of:
copolymerizing and crosslinking hydrophilic monomers, wherein said hydrophilic monomers are derived from an acrylate selected from the group consisting of formulas (III), (IV) and (V):
wherein R3 is hydrogen or methyl, R4 is an alkylene group having from about 2 to about 4 carbon atoms, and R5 and R6 may be the same or different and each is hydrogen or an alkyl radical having 1 to about 4 carbon atoms;
with hydrophobic crosslinking agents, wherein said hydrophobic crosslinking agents are multi-arm multi-telechelic polyisobutylene stars having acrylate or methacrylate end caps and represented by formula (I):
wherein R1 is polyisobutylene represented by formula (II):
wherein x is the degree of polymerization of said polyisobutylene;
wherein R2 is either H or CH3;
wherein A is a moiety that connects R1 to said acrylate or methacrylate end caps; and
wherein n is an integer from 4 to 16.

### Claim 7 (depends on 6)

The method of claim 6, wherein A comprises at least:

### Claim 8 (depends on 7)

The method of claim 7, wherein said amphiphilic polymer network is copolymerized and simultaneously crosslinked in a horizontally-disposed and rotating cylinder.

### Claim 9

An implantable biological device that is capable of encapsulating biologically active moieties, and immunoisolating said moieties from an immunological response of a host individual, said device comprising an amphiphilic network membrane comprising the reaction product of hydrophobic crosslinking agents and hydrophilic monomers, wherein said hydrophobic crosslinking agents are multi-arm multi-telechelic polyisobutylene stars having acrylate or methacrylate end caps and represented by formula (I):
wherein R1 is polyisobutylene represented by formula (II):
wherein x is the degree of polymerization of said polyisobutylene;
wherein R2 is either H or CH3;
wherein A is a moiety that connects R1 to said acrylate or methacrylate end caps;
wherein n is an integer from 4 to 16; and
wherein said hydrophilic monomers are derived from an acrylate selected from the group consisting of formulas (III), (IV) and (V):
wherein R3 is hydrogen or methyl, R4 is an alkylene group having from about 2 to about 4 carbon atoms, and R5 and R6 may be the same or different and each is hydrogen or an alkyl radical having 1 to about 4 carbon atoms.

### Claim 10 (depends on 9)

The implantable biological device of claim 9, wherein said device is an implantable tubular-shaped device.

### Claim 11 (depends on 10)

The implantable biological device of claim 10, wherein said tubular-shaped device has an inner volume of less than about 5 milliliters.

### Claim 12 (depends on 10)

The implantable biological device of claim 10, wherein said tubular-shaped device has an inner volume of less than about 1 milliliter.

### Claim 13 (depends on 10)

The implantable biological device of claim 10, wherein a membrane wall of said tubular-shaped device has thickness of about 0.001 cm to about 0.2 centimeters.

### Claim 14 (depends on 10)

The implantable biological device of claim 10, wherein the length of said tubular-shaped device is from about 1 to about 50 cm.

### Claim 15 (depends on 10)

The implantable biological device of claim 10, wherein the diameter of said tubular-shaped device is less than about 2 mm.

### Claim 16 (depends on 10)

The implantable biological device of claim 10, wherein said biologically active moieties are selected form the group consisting of cells, tissues, proteins, growth factors, pharmacological agents, and cytokines.

### Claim 17 (depends on 16)

The implantable biological device of claim 16, wherein said cells are pancreatic islet cells.

### Claim 18 (depends on 17)

The implantable biological device of claim 17, wherein said pancreatic islet cells are selected from porcine and bovine islet cells.

### Claim 19 (depends on 16)

The implantable biological device of claim 16, wherein said pharmacological agent is selected from the group consisting of anti-bacterial agents, anti-viral agents and anti-fungal agents.

### Claim 20

A method for producing an implantable biological device comprising the steps of providing an amphiphilic network comprising the reaction product of hydrophobic crosslinking agents and hydrophilic monomers, wherein said hydrophobic crosslinking agents are multi-arm multi-telechelic polyisobutylene stars having acrylate or methacrylate end caps and represented y formula (I):
wherein R1 is polyisbutylene represented by formula (II):
wherein x is the degree of polymerization of said polyisobutylene;
wherein R2 is either H or CH3;
wherein A is a moiety that connects R1 to said acrylate or methacrylate end caps;
wherein n is an integer from 4 to 16; and
wherein said hydrophilic monomers are derived from an acrylate selected from the group consisting of formulas (III), (IV) and (V):
wherein R3 is hydrogen or methyl, R4 is an alkylene group having from about 2 to about 4 carbon atoms, and R5 and R6 may be the same or different and each is hydrogen or an alkyl radical having 1 to about 4 carbon atoms; and
forming said amphiphilic network into a desired three-dimensional shape.

### Claim 21

A method for treating Type I diabetes in a diabetic host individual comprising the steps of providing an amphiphilic network comprising the reaction product of hydrophobic crosslinking agents and hydrophilic monomers, wherein said hydrophobic crosslinking agents are multi-arm multi-telechelic polyisobutylene stars having acrylate or methacrylate end caps and represented by formula (I):
wherein R1 is polyisobutylene represented by formula (II):
wherein x is the degree of polymerization of said polyisobutylene;
wherein R2 is either H or CH3;
wherein A is a moiety that connects R1 to said acrylate or methacrylate end caps;
wherein n is an integer from 4 to 16; and
wherein said hydrophilic monomers are derived from an acrylate selected from the group consisting of formulas (III), (IV) and (V):
wherein R3 is hydrogen or methyl, R4 is an alkylene group having from about 2 to about 4 carbon atoms, and R5 and R6 may be the same or different and each is hydrogen or an alkyl radical having 1 to about 4 carbon atoms;
forming said amphiphilic network into an elongated tubular device;
encasing a sufficient amount of islet of pancreatic cells within said tubular device, wherein said tubular device is capable of immunoisolating said encased islet cells upon implantation into a diabetic-host individual;
implanting said tubular device into said diabetic-host individual;
allowing said implanted tubular device to remain implanted in said diabetic-host individual for a time sufficient to normalize the blood glucose level in said diabetic-host individual.

### Claim 22 (depends on 21)

The method of claim 21, wherein the islet cells are selected from porcine and bovine pancreatic islet cells.
